Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy

Obstetrics and Gynecology

Volumn 125, Issue 5, 2015, Pages 1224-1235

  Coughlin, Catherine G ^a,b   Blackwell, Katherine A ^a,b   Bartley, Christine ^a,b   Hay, Madeleine ^a,b   Yonkers, Kimberly A ^a,b   Bloch, Michael H ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; BIRTH WEIGHT; COHORT ANALYSIS; EVIDENCE BASED PRACTICE; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HUMAN; LARGE FOR GESTATIONAL AGE; LOW BIRTH WEIGHT; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSITIVITY ANALYSIS; SMALL FOR DATE INFANT; STILLBIRTH; SYSTEMATIC REVIEW; ABNORMALITIES, DRUG-INDUCED; ADULT; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; FETUS DEVELOPMENT; HIGH RISK PREGNANCY; META ANALYSIS; PREGNANCY; PREMATURE BIRTH; PRENATAL INJURIES;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIPSYCHOTIC AGENTS; BIRTH WEIGHT; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; FETAL DEVELOPMENT; GESTATIONAL AGE; HUMANS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; PREMATURE BIRTH; PRENATAL EXPOSURE DELAYED EFFECTS; PRENATAL INJURIES;

EID: 84928138849     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000759     Document Type: Article

References (44)

1. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatric Pract 2009;15:183-92.
2. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010;36: 518-44.
3. Howard LM. Fertility and pregnancy in women with psychotic disorders. Eur J Obstet Gynecol Reprod Biol 2005;119:3-10.
4. McCauley-Elsom K, Gurvich C, Elsom SJ, Kulkarni J. Antipsychotics in pregnancy. J Psychiatr Ment Health Nurs 2010;17: 97-104.
5. Toh S, Li Q, Cheetham TC, Cooper WO, Davis RL, Dublin S, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a populationbased study of 585,615 deliveries. Arch Womens Ment Health 2013;16:149-57.
6. Epstein RA, Bobo WV, Shelton RC, Arbogast PG, Morrow JA, Wang W, et al. Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. Pharmacoepidemiol Drug Saf 2013;22:794-801.
7. Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007;164:1214-20.
8. U.S. Food and Drug Administration. FDA drug safety communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Available at: http://www.fda.gov/ Drugs/DrugSafety/ucm243903.htm. Retrieved September 16, 2014.
9. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996;153: 592-606.
10. Use of psychiatric medications during pregnancy and lactation. ACOG Practice Bulletin No. 1. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008;111: 1001-20.
11. Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010;44:99-108.
12. Abel KM. Fetal antipsychotic exposure in a changing landscape: seeing the future. Br J Psychiatry 2013;202:321-3.
13. Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open 2013;3. pii: e003062.
14. Russell FD, Burgin-Maunder CS. Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Mar Drugs 2012;10:2535-59.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34.
16. Wells GASB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Retrieved September 16, 2014.
17. Boden R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry 2012;69:715-21.
18. Kallen B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013;6: 1221-86.
19. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28: 279-88.
20. Shapiro S, Heinonen OP, Siskind V, Kaufman DW, Monson RR, Slone D. Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Benedectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977;128:480-5.
21. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977;128:486-8.
22. Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008;192:333-7.
23. Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1977;15: 57-64.
24. Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005;66:317-22.
25. Källén B. Some observations of the use during pregnancy of typical and atypical antipsychotics. Lund (Sweden): Tornblad Institute, Lund University; 2013.
26. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005;66:444-9.
27. Habermann F, Fritzsche J, Fuhlbrück F, Wacker E, Allignol A, Weber-Schoendorfer C, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol 2013;33:453-62.
28. Paulus W, Schloemp S, Sterzik K, Stoz F. Atypical antipsychotic agents in early pregnancy. Reprod Toxicol 2005;20:453-91.
29. Lin H-C, Chen I-J, Chen Y-H, Lee H-C, Wu F-J. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res 2010;116:55-60.
30. Vigod SN, Kurdyak PA, Dennis CL, Gruneir A, Newman A, Seeman MV, et al. Maternal and newborn outcomes among women with schizophrenia: a retrospective population-based cohort study. BJOG 2014;121:566-74.
31. Mei-Dan E, Ray JG, Vigod SN. Perinatal outcomes among women with bipolar disorder: a population-based cohort study. Am J Obstet Gynecol 2014 Oct 15 Epub ahead of print.
32. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-8.
33. Goncalves P, Araujo JR, Martel F. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol 2015;25:1-16.
34. Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011;93:23-58.
35. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010;67:1012-24.
36. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB; Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-5.
37. Giles JJ, Bannigan JG. Teratogenic and developmental effects of lithium. Curr Pharm Des 2006;12:1531-41.
38. Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol 2014;10:369-92.
39. Grigoriadis S, VonderPorten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 2013;74:e321-41.
40. Reichman NE, Hade EM. Validation of birth certificate data. A study of women in New Jersey's HealthStart program. Ann Epidemiol 2001;11:186-93.
41. Lieberman JA 3rd. Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry 2004;6 (suppl 2):8-13.
42. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-96.
43. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004;71: 195-212.
44. Tong VT, Jones JR, Dietz PM, D'Angelo D, Bombard JM; Centers for Disease Control and Prevention (CDC). Trends in smoking before, during, and after pregnancy-Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 sites, 2000-2005. MMWR Surveill Summ 2009; 58:1-29.